	US 11,865,112 B2
	Compositions and methods for opioid antagonist delivery
Haiyong Hugh Huang, Princeton Junction, NJ (US); and Manjunath S. Shet, White Plains, NY (US)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Filed by Purdue Pharma L.P., Stamford, CT (US)
Filed on Nov. 5, 2019, as Appl. No. 16/674,755.
Claims priority of provisional application 62/820,582, filed on Mar. 19, 2019.
Claims priority of provisional application 62/756,322, filed on Nov. 6, 2018.
Prior Publication US 2020/0138805 A1, May 7, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/395 (2006.01); A61K 31/485 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/485 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01)]

17 Claims

1. A parenteral formulation comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a parenterally acceptable adjuvant comprising magnesium chloride at a concentration ranging from about 0.5% (w/v) to about 1% (w/v), wherein the formulation provides a time to onset of opioid antagonistic action of less than 5 minutes post administration via an intramuscular or subcutaneous injection to a subject experiencing an opioid agonist overdose.